Get started
Author

Agnese Fabbri

Observed institution: Ospedale di Belcolle
ORCID: 0000-0002-3357-6343
Observed ORCID: 0000-0002-3357-6343
OpenAlex ID: A5122012931
Cumulative incidence and risk factors of trastuzumab deruxtecan–related interstitial lung disease in a multicenter real-world cohort.
2026 · Carla Gullotta, Roberta Scafetta, et al. · Journal of Clinical Oncology
Data from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S3 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S6 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S1 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S2 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S7 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S4 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S5 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Table S2 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S9 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S8 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Table S1 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Works count: 13
Citation count:
H-index:
I10-index:
Year
Topic
Type